Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Paweł, Teterycz"'
Autor:
Aleksandra Piórek, Adam Płużański, Magdalena Knetki-Wróblewska, Kinga Winiarczyk, Sylwia Tabor, Paweł Teterycz, Dariusz M. Kowalski, Maciej Krzakowski
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Objective Primary tracheal tumors are very rare and their management is not definitely established. Due to its rarity, providing patient care in terms of optimal management poses a considerable challenge. The purpose of this study was to inv
Externí odkaz:
https://doaj.org/article/f336479d0584403891e32a04fc573303
Autor:
Aleksandra Piórek, Adam Płużański, Paweł Teterycz, Sylwia Tabor, Kinga Winiarczyk, Magdalena Knetki‐Wróblewska, Dariusz M. Kowalski, Maciej Krzakowski
Publikováno v:
Thoracic Cancer, Vol 15, Iss 11, Pp 878-883 (2024)
Abstract Background Primary tracheal tumors are very rare and the literature on this subject is limited. The most common histological type of primary tracheal tumors is squamous cell carcinoma (SCC), followed by adenoid cystic carcinoma (ACC). Limite
Externí odkaz:
https://doaj.org/article/daa7c1b39e7e43acbc6773ed02dee4b8
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Introduction: Selected patients with locally advanced or metastatic soft tissue and bone sarcomas (STBS) may benefit from intensive local treatment, such as stereotactic radiotherapy (SRT). This study aimed to summarize the utilization and outcomes o
Externí odkaz:
https://doaj.org/article/1915a3476a294f31b49827ef3cc80141
Autor:
Marcin Ziętek, Paweł Teterycz, Jędrzej Wierzbicki, Michał Jankowski, Manuela Las-Jankowska, Wojciech Zegarski, Janusz Piekarski, Dariusz Nejc, Kamil Drucis, Bożena Cybulska-Stopa, Wojciech Łobaziewicz, Katarzyna Galwas, Grażyna Kamińska-Winciorek, Marcin Zdzienicki, Tatsiana Sryukina, Anna Ziobro, Agnieszka Kluz, Anna M. Czarnecka, Piotr Rutkowski
Publikováno v:
Cancers; Volume 15; Issue 10; Pages: 2667
Background: In melanoma treatment, an approach following positive sentinel lymph node biopsy (SLNB) has been recently deescalated from completion lymph node dissection (CLND) to active surveillance based on phase III trials data. In this study, we ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93c27954d8a66aa627841dfedc7232f8
Autor:
Tomasz Świtaj, Tadeusz Morysiński, Piotr Rutkowski, Hanna Koseła-Paterczyk, Anna M. Czarnecka, Paweł Sobczuk, Marcin Zdzienicki, Tomasz Goryń, Paweł Teterycz, Katarzyna Kozak, Sławomir Falkowski
Publikováno v:
Surgical Oncology. 35:276-284
Introduction Malignant peripheral nerve sheath tumor (MPNST) accounts for about 5% of soft tissue sarcomas. It can occur as sporadic diseases or can be associated with type 1 neurofibromatosis. MPNST is usually associated with poor prognosis, mostly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce1f9b225a026f774a550062b9b8b08b
https://doi.org/10.1016/j.suronc.2020.09.011
https://doi.org/10.1016/j.suronc.2020.09.011
Autor:
Aleksandra Piórek, Adam Płużański, Paweł Teterycz, Dariusz Mirosław Kowalski, Maciej Krzakowski
Publikováno v:
Cancers; Volume 14; Issue 7; Pages: 1665
Due to the low incidence of primary tracheal neoplasms, there is no uniform system for staging of this disease. Our retrospective analysis based on registry data included 89 patients diagnosed with primary tracheal cancer at the National Research Ins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cbaec83c4f76bcb4e1b1567fce5c65d
https://pubmed.ncbi.nlm.nih.gov/35406437
https://pubmed.ncbi.nlm.nih.gov/35406437
Autor:
Paweł Teterycz, Paulina Jagodzińska-Mucha, Tomasz Świtaj, Piotr Rutkowski, Paweł Rogala, Hanna Koseła-Paterczyk, Katarzyna Kozak
Publikováno v:
Oncology in Clinical Practice. 16:109-115
Introduction. Combined inhibition of BRAF and MEK improved progression-free survival and overall survival in patients with BRAFV600-mutation-positive metastatic melanoma. We conducted a retrospective study on real-life patients with BRAF-mutant melan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a90ce9e7b70a9c19efe1da2ae6d79ba3
https://doi.org/10.5603/ocp.2020.0017
https://doi.org/10.5603/ocp.2020.0017
Autor:
Anna Szumera-Ciećkiewicz, Mateusz Spałek, Piotr Rutkowski, Paweł Teterycz, Anna M. Czarnecka, Aneta Borkowska, Artur Kowalik
Publikováno v:
Oncotarget
Background Specific genomic profile of cutaneous melanomas is related to UVR exposure, which exerts biological and therapeutic impact. Subungual melanoma (SUM) is an exceedingly rare disease; therefore, it is not well characterized. SUM pathogenesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca198dceeeaf375b82f717afbd5e1d4f
https://doi.org/10.18632/oncotarget.27642
https://doi.org/10.18632/oncotarget.27642
Autor:
Piotr Rutkowski, Paweł Rogala, Magdalena Wiśniewska, Anna M. Czarnecka, Adrianna Gęga-Czarnota, Bożena Cybulska-Stopa, Łukasz Galus, Tomasz Kubiatowski, Paweł Teterycz, Marcin Rajczykowski, Jacek Mackiewicz, Marek Ziobro, Robert Dziura, Rafał Suwiński
Publikováno v:
Melanoma Research. 30:465-471
Despite considerable progress made in the treatment of patients with advanced melanoma, the majority of the patients treated with BRAF and mitogen-activated protein inhibitors (BRAFi and MEKi) experience a disease progression due to acquired resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8926c33a75ea08f76d9b5656c058b61a
https://doi.org/10.1097/cmr.0000000000000662
https://doi.org/10.1097/cmr.0000000000000662
Autor:
Joanna Kalisz, Natalia Krawczynska, Tomasz Switaj, Katarzyna Kozak, Małgorzata Chłopek, Monika Jurkowska, Janusz Limon, Aleksandra Gos, Piotr Rutkowski, Paweł Teterycz, Hanna Koseła-Paterczyk, Artur Kowalik, Iwona Lugowska, Janusz A. Siedlecki, Anna Klimczak, Bartosz Wasag
Publikováno v:
Tumori Journal. 106:241-248
Objective: We assessed the status of the BRAF V600E mutation in cell-free circulating tumor DNA (cfDNA) isolated from the plasma of patients with metastatic melanoma treated with the BRAF inhibitor vemurafenib, collected at different time points duri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::416528782e173a1a30fb86f5bdf5f67a
https://doi.org/10.1177/0300891619900928
https://doi.org/10.1177/0300891619900928